Insider Trading Activity Emergent Biosolutions, Inc. (NYSE:EBS) – Chairman Sold 25,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Emergent Biosolutions, Inc. (NYSE:EBS)

Fuad El-Hibri , Chairman of Emergent Biosolutions, Inc. (NYSE:EBS) reportedly Sold 25,000 shares of the company’s stock at an average price of 35.5 for a total transaction amount of $887,500.00 SEC Form

Insider Trading History For Emergent Biosolutions, Inc. (NYSE:EBS)

  • On 3/11/2014 Adam Havey, EVP, sold 17,655 with an average share price of $26.96 per share and the total transaction amounting to $475,978.80.View SEC Filing
  • On 3/12/2014 Adam Havey, EVP, sold 11,562 with an average share price of $27.50 per share and the total transaction amounting to $317,955.00.View SEC Filing
  • On 4/16/2014 Robert Kramer, CFO, sold 50,189 with an average share price of $24.34 per share and the total transaction amounting to $1,221,600.26.View SEC Filing
  • On 11/7/2014 Robert Kramer, CFO, sold 2,625 with an average share price of $24.00 per share and the total transaction amounting to $63,000.00.View SEC Filing
  • On 11/12/2014 Fuad El-Hibri, Major Shareholder, sold 2,311 with an average share price of $25.00 per share and the total transaction amounting to $57,775.00.View SEC Filing
  • On 11/25/2014 Zsolt Harsanyi, Director, sold 8,000 with an average share price of $24.82 per share and the total transaction amounting to $198,560.00.View SEC Filing
  • On 11/25/2014 Fuad El-Hibri, Major Shareholder, sold 9,014 with an average share price of $25.00 per share and the total transaction amounting to $225,350.00.View SEC Filing

    • Analyst Ratings For Emergent Biosolutions, Inc. (NYSE:EBS)
    These are 1 Hold Rating, 3 Buy Ratings .
    The current consensus rating for Emergent Biosolutions, Inc. (NYSE:EBS) is Buy (Score: 2.75) with a consensus target price of $39.25 , a potential (9.30% upside)

    Analyst Ratings History For Emergent Biosolutions, Inc. (NYSE:EBS)

    • On 6/28/2016 Singular Research Lower Price Target of rating Buy with a price target of $44.00 to $40.00
    • On 8/5/2016 J P Morgan Chase & Co Lower Price Target of rating Overweight with a price target of $45.00 to $36.00
    • On 10/1/2016 Wells Fargo & Company Set Price Target of rating Buy with a price target of $41.00
    • On 1/9/2017 Cowen and Company Reiterated Rating Hold
    • On 1/30/2017 Chardan Capital Reiterated Rating Buy with a price target of $47.00

    Recent Trading Activity for Emergent Biosolutions, Inc. (NYSE:EBS)
    Shares of Emergent Biosolutions, Inc. closed the previous trading session at 35.91 down -0.13 -0.36% with 271,248 shares trading hands.